Next Article in Journal
The Signal Peptide and Chaperone UNC93B1 Both Influence TLR8 Ectodomain Intracellular Endosomal Localization
Previous Article in Journal
Adults’ Acceptance of COVID-19 Vaccine for Children in Selected Lower- and Middle-Income Countries
Article

Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study

1
Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy
2
Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy
3
Department of Molecular Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Ger Rijkers and Jean-Luc Murk
Vaccines 2022, 10(1), 12; https://doi.org/10.3390/vaccines10010012
Received: 29 November 2021 / Revised: 20 December 2021 / Accepted: 21 December 2021 / Published: 23 December 2021
(This article belongs to the Topic Global Analysis of SARS-CoV-2 Serology)
Objective: To evaluate the safety and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in gynecologic oncology patients under chemotherapy. Methods: A prospective cohort study including gynecologic oncology women who were under chemotherapy or had completed it within 6 months at the time of the study. All patients received a two-dose schedule of the Pfizer-BioNTech COVID-19 vaccine. Results were compared with a control group of healthy women vaccinated in the same period. Results: Overall, 44 oncologic patients with a mean age of 61.3 ± 10.7 years were enrolled: 28 (63.6%) had ovarian cancer, 9 (20.4%) endometrial, and 7 (16%) cervical. The IgG antibody titer after 1 month from vaccination was low in 9 (20.5%) patients, moderate in 21 (47.7%), and high in 14 (31.8%). The 3-month titer was null in 2 (4.5%) patients, low in 26 (59.1%), moderate in 13 (29.5%), and high in 3 (6.8%). Patients ≥ 50 years reported lower 1-month (p = 0.018) and 3-month (p = 0.004) titers compared with <50 years. Patients with BMI < 30 kg/m2 had a higher 1-month titer compared with BMI ≥ 30 kg/m2 (p = 0.016). Compared with healthy women (n = 44), oncologic patients showed a lower 3-month titer (p < 0.001). None of the patients experienced serious adverse effects. Conclusions: The COVID-19 vaccine was safe and immunogenic in gynecologic oncology patients under chemotherapy. Serological monitoring and further vaccine shots should be considered to boost protection. View Full-Text
Keywords: COVID-19; SARS-CoV-2; cancer; gynecologic oncology; vaccine; chemotherapy COVID-19; SARS-CoV-2; cancer; gynecologic oncology; vaccine; chemotherapy
MDPI and ACS Style

Palaia, I.; Caruso, G.; Di Donato, V.; Vestri, A.; Napoli, A.; Perniola, G.; Casinelli, M.; Alunni Fegatelli, D.; Campagna, R.; Tomao, F.; D’Aniello, D.; Antonelli, G.; Muzii, L. Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study. Vaccines 2022, 10, 12. https://doi.org/10.3390/vaccines10010012

AMA Style

Palaia I, Caruso G, Di Donato V, Vestri A, Napoli A, Perniola G, Casinelli M, Alunni Fegatelli D, Campagna R, Tomao F, D’Aniello D, Antonelli G, Muzii L. Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study. Vaccines. 2022; 10(1):12. https://doi.org/10.3390/vaccines10010012

Chicago/Turabian Style

Palaia, Innocenza, Giuseppe Caruso, Violante Di Donato, Annarita Vestri, Anna Napoli, Giorgia Perniola, Matteo Casinelli, Danilo Alunni Fegatelli, Roberta Campagna, Federica Tomao, Debora D’Aniello, Guido Antonelli, and Ludovico Muzii. 2022. "Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study" Vaccines 10, no. 1: 12. https://doi.org/10.3390/vaccines10010012

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop